![Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI](https://cedclinic.com/wp-content/uploads/2026/06/ced-pexels-4226264-1-150x150.jpg "Assay: Irreversible inhibition of rat brain cytosolic MAGL assessed as [3H] - EMBL-EBI 17")
Associations Between Cannabis Use and Inflammatory Biomarkers Among People with HIV.
Table of Contents
Associations Between Cannabis Use and Inflammatory Biomarkers Among People with HIV.
Current cannabis use was associated with lower inflammatory biomarkers in people with HIV who achieved viral suppression on antiretroviral therapy.
This cross-sectional analysis suggests current cannabis use may correlate with reduced systemic inflammation in virally suppressed people with HIV. The study provides observational evidence that cannabis use patterns differ in their association with inflammatory markers in this population.
People with HIV experience persistent immune activation despite effective antiretroviral therapy, contributing to accelerated aging and comorbidities. If cannabis genuinely modulates inflammation in this context, it could inform discussions about potential benefits and risks of cannabis use in HIV care.
| Study Type | Cross-sectional Cohort Analysis |
| Population | 532 people with HIV on antiretroviral therapy with viral suppression |
| Intervention | Self-reported cannabis use categorized as Never, Former, or Current (past 3 months) |
| Comparator | Never users and former users |
| Primary Outcome | Thirteen plasma inflammatory biomarkers measured once |
| Key Finding | Current cannabis use associated with lower inflammatory biomarker levels compared to never/former use |
| Journal | Cannabis and Cannabinoid Research |
| Year | 2024 |
Among virally suppressed people with HIV, current cannabis users showed lower inflammatory biomarkers than non-users. This observational finding requires replication and mechanistic validation before informing clinical recommendations.
This study cannot establish causation between cannabis use and reduced inflammation. It does not demonstrate clinical benefits, optimal dosing, delivery methods, or long-term outcomes. The findings may not apply to people with detectable viral loads or different HIV disease stages.
Cross-sectional design prevents causal inference. Unmeasured confounders could explain the association – healthier individuals might be more likely to use cannabis. Self-reported cannabis use lacks standardization for dose, frequency, or cannabinoid content. Single biomarker measurements may not reflect chronic inflammatory status.
Want to apply this research to your care?
CED Clinic translates emerging research into individualized clinical care. Dr. Caplan has treated 30,000+ patients.
Book a consultation →Current cannabis users with suppressed HIV showed lower inflammatory markers in this observational study. While mechanistically interesting, this single cross-sectional analysis cannot establish cannabis as an anti-inflammatory intervention. Clinical decisions should await prospective controlled studies.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Does cannabis use affect inflammation in people with HIV?
This study found that current cannabis use was associated with lower inflammatory biomarkers in people with HIV who achieved viral suppression on antiretroviral therapy. The research examined 13 plasma biomarkers among 532 participants and suggests cannabis may have anti-inflammatory effects in this population.
The study focused on participants who were virally suppressed on antiretroviral therapy and found associations with reduced inflammation markers. However, this observational study cannot establish causation or comprehensive safety, and patients should discuss cannabis use with their HIV care providers to evaluate individual risks and benefits.
How was cannabis use measured in this study?
Cannabis use was categorized as Never, Former, or Current (past 3-month) use based on self-reported data collected within 1 year prior to biomarker collection. The study specifically examined current use patterns rather than dosing, frequency, or method of consumption.
What inflammatory biomarkers were affected by cannabis use?
The study measured 13 plasma inflammatory biomarkers, though the specific biomarkers and magnitude of reduction are not detailed in the provided summary. The biomarkers were log-transformed and standardized to allow for comparison across different inflammatory markers.
Can these findings guide clinical recommendations for HIV patients?
While the association between cannabis use and lower inflammation is notable, this observational study cannot establish causation or clinical benefit. Healthcare providers should consider this emerging evidence alongside other factors when discussing cannabis use with HIV patients, particularly those with chronic inflammation concerns.
